Clinical Trials Browser

Pathologic Complete Response, Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Squamous Cell Carcinoma of Head and Neck

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

Breast Neoplasms, Neoplasms

Breast Neoplasms

Stomach Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasm Female

Breast Neoplasms

Breast Neoplasms

Esophageal Squamous Cell Carcinoma

Breast Neoplasms

HER2-positive Breast Cancer

HER2+ Breast Cancer

Breast Neoplasms

Brain Neoplasms, Breast Neoplasms

Breast Neoplasms

HER2-positive Gastric Cancer

Breast Neoplasms

Intestinal Neoplasms, Colorectal Neoplasms

HER2-positive Breast Cancer

HER2-positive Breast Cancer

Estrogen Receptor-positive Breast Cancer

Colorectal Neoplasms

Breast Neoplasms, Cardiotoxicity

Digestive System Neoplasms

Breast Neoplasms, Cardiotoxicity

Breast Neoplasms

Brain Neoplasms

HER2+ Early or Locally Advanced Breast Cancer

Stomach Neoplasms

Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer

Stomach Neoplasms

Stomach Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Relapsed Pediatric Solid Tumor

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Clinical Trials

Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer

Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

B2023-153

ROME

BiOnHER

HIST-RIC

Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC

Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer

VinCaT

easy laugh

NeoPATH

Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer

Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)

Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer

HERES

A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer

Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients

Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China

Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab

Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer

Efficacy and Safety of Precision Therapy in Refractory Tumor

A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast Cancer

Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer

Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer

a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors

HERMET

NeoTPPF

A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal Cancer

Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients

Efficacy and Safety of Pyrotinib in HER2 Positive Gastrointestinal Tumors

Evaluation of Heart Function in Breast Cancer Patients Using Trastuzumab

Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)

Pyramid

Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)

Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast Cancer

Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer

B-DOCT

Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer

Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC

Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis

FAVOR

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

SOBER

Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer

Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer

A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.